BTAI vs OGN · rev $388.0K vs P/E 3.4, rev $3.02B
BioXcel Therapeutics Inc (BTAI) versus Organon & Co (OGN) — a side-by-side from cached financials, not a winner call.
BioXcel Therapeutics Inc (BTAI) is a drug manufacturers - specialty & generic company listed on US.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Latest reported BTAI revenue for 2026-06-30 was $388.0K. Net income was -$27.4M. Revenue was up 88.3% from 2026-03-31 to 2026-06-30. BTAI currently screens at market cap $36.1M.
Latest reported OGN revenue for 2026-06-30 was $3.02B. Net income was $254.0M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
BTAI currently screens at market cap $36.1M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Not investment advice. Open the BTAI and OGN stock pages for the full models.
Not investment advice.